Berlin - Delayed Quote • EUR Defence Therapeutics Inc (DTC.BE) Follow Add holdings 0.5980 +0.0020 +(0.34%) As of 6:35:05 PM GMT+2. Market Open. Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for DTC.BE 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: DTC.BE View More All News Press Releases SEC Filings Defence Launches Accum Combined with Actinium-225 to Increase Efficacy and Safety of Radio-Immunoconjugate Cancer Therapies Defence Announces US Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Defence's Management Team as Chief Operating Officer Defence Closes Second Tranche of Fully Subscribed Financing Totaling $4.2 Million Defence to Connect with Industry Leaders and Potential Partners During the JP Morgan Healthcare Conference in San Francisco. Plans to Expand the Next Generation of Radio-Immuno Conjugates in 2025 Defence Fortifies Patent Portfolio Defence Arranges Financing Defence Announces Molecular and Antibody Research Expert Dr. Elias Theodorou Joins Its Board of Directors Defence Provides Update on Delivery of AGSM Proxy Materials Defence's Proprietary Accum Technology Ready to License to Companies Developing Antibody Drug Conjugates (ADC) Defence Announces Dr. Maxime Parisotto as CSO, Director of Science and Business Development Defence Announces Closing of Securities for Debenture Financing